Immune-checkpoint inhibitors in pituitary malignancies.
Adrenocorticotropic Hormone
/ biosynthesis
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Growth Hormone
/ biosynthesis
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Ipilimumab
/ therapeutic use
Neoplasm Metastasis
Nivolumab
/ therapeutic use
Pituitary Neoplasms
/ drug therapy
Tumor Microenvironment
/ drug effects
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
5
8
2021
medline:
3
3
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
To date, there are no standardized systemic treatment options for patients with metastatic pituitary carcinoma progressed to chemo and radiation therapy. Immune-checkpoint inhibitors (ICIs) have been successfully assessed in other solid malignancies and could be a concrete hope for these patients. We performed a critical review of the literature aimed to evaluate studies assessing ICIs in pituitary malignancies. We also conducted research about published translational data assessing immune-contexture in these malignancies. Some preliminary reports reported a successful administration of pembrolizumab or the combination between nivolumab and ipilimumab in patients with metastatic ACTH-secreting pituitary carcinomas. Translational data suggest that adenomas secreting growth hormone and ACTH have a suppressed immune-microenvironment, which could be more likely to benefit from ICIs. Immune-checkpoint inhibitors can be an effective treatment in patients with pituitary carcinoma and maybe also recurrent adenoma. Tumors secreting growth hormone and ACTH are more likely to benefit from ICIs due to a different immune-microenvironment.
Identifiants
pubmed: 34348358
doi: 10.1097/CAD.0000000000001157
pii: 00001813-202201000-00019
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Adrenocorticotropic Hormone
9002-60-2
Growth Hormone
9002-72-6
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28-e35Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017; 134:521–535.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91:4769–4775.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377–382.
Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R, et al. Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev 2014; 37:279–285.
Franceschi E, Frappaz D, Rudà R, Hau P, Preusser M, Houillier C, et alEURACAN Domain 10. Rare primary central nervous system tumors in adults: an overview. Front Oncol 2020; 10:996.
Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 2014; 170:R121–R132.
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et alEuropean Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018; 178:G1–G24.
Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017; 317:516–524.
Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med 2020; 382:937–950.
Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 2014; 74:E447–E455.
Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 2020; 20:75–76.
Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol 2020; 83:1239–1253.
Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med 2020; 9:E1362.
Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, et al. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy 2019; 11:1507–1521.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 2018; 64:11–20.
von der Grün J, Rödel F, Brandts C, Fokas E, Guckenberger M, Rodel C, et al. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: where do we stand today and where to go? Cancers (Basel) 2019; 11:472.
Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol 2019; 12:111.
Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, et al. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019; 12:42.
Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol 2020; 17:279–299.
Sol B, de Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol 2021; 184:K1–K5.
Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 2018; 103:3925–3930.
Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 2016; 7:76565–76576.
Rossi ML, Jones NR, Esiri MM, Havas L, al Izzi M, Coakham HB. Mononuclear cell infiltrate and HLA-Dr expression in 28 pituitary adenomas. Tumori 1990; 76:543–547.
Heshmati HM, Kujas M, Casanova S, Wollan PC, Racadot J, Van Effenterre R, et al. Prevalence of lymphocytic infiltrate in 1400 pituitary adenomas. Endocr J 1998; 45:357–361.
Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL. Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocr Pathol 2015; 26:263–272.
Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. J Neurooncol 2020; 147:595–598.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549–555.
Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol 2020; 15:123–147.
Passardi A, Scarpi E, Cavanna L, Dall’Agata M, Tassinari D, Leo S, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016; 7:33210–33219.
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 2016; 99(Pt B):180–185.
Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 2019; 7:172.
Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene 2019; 38:5381–5395.
Yagnik G, Rutowski MJ, Shah SS, Aghi MK. Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget 2019; 10:2212–2223.
Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y, et al. Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors. J Clin Med 2019; 8:E695.
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease. Clin Cancer Res 2020; 26:1141–1151.
Principe M, Chanal M, Ilie MD, Ziverec A, Vasiljevic A, Jouanneau E, et al. Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion. J Clin Endocrinol Metab 2020; 105:dgaa520.
Zhou W, Zhang C, Zhang D, Peng J, Ma S, Wang X, et al. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. J Neurooncol 2020; 149:473–487.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991–998.
Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget 2017; 8:7175–7180.
Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine 2020; 67:651–658.
Duhamel C, Ilie MD, Salle H, Nassouri AS, Gaillard S, Deluche E, et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature. J Pers Med 2020; 10:E88.
Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer 2020; 8:e001532.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020; 8:e000347.
Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res 2021; 27:1236–1241.
Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, et al. The Predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysisEur Urol 2020; 79:783–792.
Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018; 362:k3529.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 2020; 10:1808–1825.
Zhou H, Liu J, Zhang Y, Fang W, Zhang L. Combined model of frameshift mutations and tumor mutation burden in predicting preliminary response to immune checkpoint inhibitors in NSCLC. J Thorac Oncol 2019; 14:e271–e273.
Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Reggiani MLB, et al. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III [published correction appears in Mol Oncol. 2015 Jan;9(1):334] [published correction appears in Mol Oncol. 2015 Jan;9(1):334]Mol Oncol 2014; 8:417–430.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et alKEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375:1823–1833.
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23:703–713.
Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008; 89:179–185.
McDonald KA, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J, et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann Surg Oncol 2019; 26:2191–2199.
Di Nunno V, Franceschi E, Gatto L, Bartolini S, Brandes AA. Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncol 2020; 16:1053–1063.
Di Nunno V, Franceschi E, Tosoni A, Di Battista M, Gatto L, Lamperini C, et al. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther 2020; 20:785–795.
Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et alMembers of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126:123–135.
Honegger J, Zimmermann S, Psaras T, Petrick M, Mittelbronn M, Ernemann U, et al. Growth modelling of non-functioning pituitary adenomas in patients referred for surgery. Eur J Endocrinol 2008; 158:287–294.
Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, et al. Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 2017; 23:1841–1851.
Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology 2015; 101:87–104.
Fountas A, Lavrentaki A, Subramanian A, Toulis KA, Nirantharakumar K, Karavitaki N. Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab 2018. doi: 10.1210/jc.2018-01956. [Epub ahead of print]
doi: 10.1210/jc.2018-01956.
Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, et al. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 2017; 102:3368–3374.
Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K. Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat Rev Endocrinol 2014; 10:423–435.